DRMA Dermata Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why DRMA matters now
Dermata Therapeutics, Inc. (DRMA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.63 with +14.79% on the session and $1.1M in market capitalization; recent performance reads 1-month -0.85% and YTD -49.57%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.8M, and EPS of $-0.48. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1041.3%.
The latest indexable market news headline is "Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch" from Accesswire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Scott Kathleen D. filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.70
P/S
0.00
EV/EBITDA
0.87
DCF Value
$7.66
FCF Yield
-1041.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-127.9%
ROA
-95.1%
ROIC
-114.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-1.8M | $-0.48 |
| Q4 2025 | $0.00 | $-1.9M | $-1.52 |
| FY 2025 | $0.00 | $-7.6M | $-8.16 |
| Q3 2025 | $0.00 | $-1.7M | $-1.65 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.69
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.